Kidney Health Gateway
Back to all trials
Currently Enrolling
Interventional

The AFFINITY Study

Atrasentan for Patients with Proteinuric Glomerular Diseases

Brief Description

The AFFINITY study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy, focal segmental glomerulosclerosis, Alport Syndrome, and diabetic kidney disease.

Trial Physician / Study Coordinator

Dr. Ciro Esposito

Email Phone +1(206) 485-7051
Site Name

Fondazione Salvatore Maugeri IRCCS
Via Salvatore Maugeri,10/10a, Lombardy, Pavia 27100

Sponsor

Chinook Therapeutics

Study Drug

Atrasentan

Estimated enrollment

80

Estimated end date

December 2024

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Currently Enrolling
Interventional

The AFFINITY Study

Atrasentan for Patients with Proteinuric Glomerular Diseases

Brief Description

The AFFINITY study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy, focal segmental glomerulosclerosis, Alport Syndrome, and diabetic kidney disease.

Trial is for people with

Iga Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), and Diabetic Kidney Disease (DKD)

Study Goal

The goal of the study is to evaluate the effect of atrasentan on proteinuria in patients with IgAN, FSGS, Alport Syndrome, or in combination with SGLT2 inhibitors in DKD.

What is involved for the Patient?

Patients will participate for about 1 year and will receive atrasentan.

About the drug or intervention

Atrasentan is a tablet taken orally once a day.

Find other locations for this trial:
Lombardy, Pavia, Italy (Fondazione Salvatore Maugeri IRCCS)
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions